Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
The department will soon release a policy to catalyze research & development and innovation in the pharma- Medtech sector in India
Subscribe To Our Newsletter & Stay Updated
